CRDF - Cardiff Oncology GAAP EPS of -$0.20 beats by $0.06 revenue of $0.09M beats by $0.02M
- Cardiff Oncology press release ( NASDAQ: CRDF ): Q3 GAAP EPS of -$0.20 beats by $0.06 .
- Revenue of $0.09M (+12.5% Y/Y) beats by $0.02M .
- Shares +0.7% .
- Cash, cash equivalents, and short-term investments of approximately $114 million as of September 30, 2022, provide projected runway into 2025
For further details see:
Cardiff Oncology GAAP EPS of -$0.20 beats by $0.06, revenue of $0.09M beats by $0.02M